For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
DelveInsight's, "Hypertriglyceridemia - Pipeline Insight, 2021," report provides comprehensive insights about 22+ companies and 22+ pipeline drugs in Hypertriglyceridemia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hypertriglyceridemia Understanding
Hypertriglyceridemia: Overview
Hypertriglyceridemia refers to an elevated level of triglycerides (a type of lipid) in the bloodstream, a condition that increases the risk of coronary artery disease. The triglycerides found in our bloodstream are a mixture of triglycerides that have been obtained from the diet and those produced in the body to provide an energy source. Hypertriglyceridemia is often caused or worsened by factors such as obesity, poorly controlled diabetes and a sedentary lifestyle. The most common reasons for hypertriglyceridemia developing are obesity, lack of physical activity, type 2 diabetes, metabolic syndrome and familial hyperlipidemia, a genetic condition that causes high triglycerides and low levels of the "good" cholesterol, HDL (high-density lipoprotein).
"Hypertriglyceridemia - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertriglyceridemia pipeline landscape is provided which includes the disease overview and Hypertriglyceridemia treatment guidelines. The assessment part of the report embraces, in depth Hypertriglyceridemia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertriglyceridemia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Hypertriglyceridemia R&D. The therapies under development are focused on novel approaches to treat/improve Hypertriglyceridemia.
Hypertriglyceridemia Emerging Drugs Chapters
This segment of the Hypertriglyceridemia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hypertriglyceridemia Emerging Drugs
- ARO-APOC3: Arrowhead Pharmaceuticals
ARO-APOC3 is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including VLDL and chylomicrons and is a key regulator of triglyceride metabolism. The company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants.
- MND-21: Mochida Pharmaceutical
MND-21, a therapeutic agent for hypertriglyceridemia which is being developed in collaboration with Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. in China. Currently, it is in Phase III stage of clinical trial evaluation to treat Hypertriglyceridaemia.
Further product details are provided in the report ..
Hypertriglyceridemia: Therapeutic Assessment
This segment of the report provides insights about the different Hypertriglyceridemia drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Hypertriglyceridemia
There are approx. 22+ key companies which are developing the therapies for Hypertriglyceridemia. The companies which have their Hypertriglyceridemia drug candidates in the most advanced stage, i.e. phase III include, Mochida Pharmaceutical.
- Phases
DelveInsight's report covers around 22+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Hypertriglyceridemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Oral
- Parenteral
- intravenous
- Subcutaneous
- Topical.
- Molecule Type
Products have been categorized under various Molecule types such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Hypertriglyceridemia: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypertriglyceridemia therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertriglyceridemia drugs.
Hypertriglyceridemia Report Insights
- Hypertriglyceridemia Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Hypertriglyceridemia Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Questions
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hypertriglyceridemia drugs?
- How many Hypertriglyceridemia drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hypertriglyceridemia?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Hypertriglyceridemia therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hypertriglyceridemia and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Arrowhead Pharmaceuticals
- Mochida Pharmaceutical
- Ionis Pharmaceuticals
- 89bio
- Regeneron Pharmaceuticals
- Acasti Pharma Inc.
- Staten Biotechnology BV
- NorthSea Therapeutics B.V.
- Afimmune
- Rivus Pharmaceuticals
- Novo Nordisk
- Viking Therapeutics
- Liminal BioSciences
- Matinas BioPharma
- Arbutus Biopharma
- Better Therapeutics
Key Products
- ARO-APOC3
- MND-21
- IONIS-APOCIII-LRx
- BIO89-100
- Evinacumab
- CaPre
- STT-5058
- NST-1024
- DS102
- AKCEA-APOCIII-LRx
- NST-4016
- BT-005
- HU 6
- TKM-HTG
- COR 003
- MAT-9001
- VK 1430
- PBI 4050